Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention

This study has been completed.
Information provided by:
Samsung Medical Center Identifier:
First received: January 27, 2008
Last updated: March 2, 2011
Last verified: March 2011
The purpose of this study to determine whether statin pretreatment decrease myocardial infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

Condition Intervention
Angioplasty, Transluminal, Percutaneous Coronary
Drug: atorvastatin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

Resource links provided by NLM:

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • Myocardial infarct size by SPECT [ Time Frame: between 5 and 14 days after acute myocardial infarction ]

Secondary Outcome Measures:
  • Myocardial infarct size measured by contrast-enhanced MRI [ Time Frame: within 14 days after acute myocardial infarction ]
  • Myocardial blush grade after the procedure [ Time Frame: immediate after procedure ]
  • complete ST resolution [ Time Frame: at 60 minutes after the procedure ]
  • major adverse cardiac events related to left ventricular dysfunction (death, new-onset sustained hypotension or heart failure, and hospital readmission for left ventricular dysfunction) [ Time Frame: at 6 months after the procedure ]

Enrollment: 173
Study Start Date: July 2007
Study Completion Date: August 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Atorvastatin group
Drug: atorvastatin
atorvastatin 80mg/day before primary coronary intervention
No Intervention: 2
Control group


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
  • ST segment elevation more than 1 mm in two or more contiguous leads or presumably a new onset left bundle branch blockage

Exclusion Criteria:

  • Cardiogenic shock
  • History of myocardial infarction
  • Chronic liver disease
  • Previous or current statin use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00610870

Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Samsung Medical Center
Principal Investigator: Hyeon-Cheol Gwon, MD, PhD Samsung Medical Center
  More Information

Responsible Party: HC Gwon, MD,PhD / Professor, Samsung Medical Center Identifier: NCT00610870     History of Changes
Other Study ID Numbers: 2007-04-049
Study First Received: January 27, 2008
Last Updated: March 2, 2011

Keywords provided by Samsung Medical Center:
Myocardial infarct size
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Additional relevant MeSH terms:
Atorvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Enzyme Inhibitors processed this record on May 25, 2017